A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study

被引:5
作者
Adiwidjaja, Jeffry [1 ]
Boddy, Alan, V [1 ,2 ]
McLachlan, Andrew J. [1 ]
机构
[1] Univ Sydney, Sydney Pharm Sch, Sydney, NSW, Australia
[2] Univ South Australia, Sch Pharm & Med Sci, Adelaide, SA, Australia
来源
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY | 2018年 / 7卷 / 12期
关键词
IN-VIVO EXTRAPOLATION; INTERINDIVIDUAL VARIABILITY; CYTOCHROME-P450; 3A4; VITRO DATA; PHARMACODYNAMICS; TRANSPORTERS; METABOLISM; PROBE; SIMVASTATIN; REPAGLINIDE;
D O I
10.1002/psp4.12355
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The phenotyping approach to predict drug metabolism activity is often hampered by a lack of correlation between the probe and the drug of interest. In this article, we present a strategy to refine the phenotyping approach based on a physiologically based pharmacokinetic simulation (implemented in Simcyp Simulator version 17) using previously published models. The apparent clearance (CL/F) of erlotinib was better predicted by the sum of caffeine and i.v. midazolam CL/F (r(2) = 0.60) compared to that of either probe drug alone. The clearance of atorvastatin and repaglinide had a strong correlation (r(2) = 0.70 and 0.63, respectively) with that of pitavastatin (a SLCO1B1 probe). Use of multiple probes for drugs that are predominantly metabolized by more than one cytochrome P450 (CYP) enzyme should be considered. In a case in which hepatic uptake transporters play a significant role in the disposition of a drug, the pharmacokinetic of a transporter probe will provide better predictions of the drug clearance.
引用
收藏
页码:798 / 808
页数:11
相关论文
共 49 条
[1]   Changes in plasma protein binding have little clinical relevance [J].
Benet, LZ ;
Hoener, BA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) :115-121
[2]   Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis [J].
Burt, Howard J. ;
Riedmaier, Arian Emami ;
Harwood, Matthew D. ;
Crewe, H. Kim ;
Gill, Katherine L. ;
Neuhoff, Sibylle .
DRUG METABOLISM AND DISPOSITION, 2016, 44 (10) :1550-1561
[3]   Comparison of midazolam and simvastatin as cytochromc P450 3A probes [J].
Chung, E ;
Nafziger, AN ;
Kazierad, DJ ;
Bertino, JS .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) :350-361
[4]   Prediction of Human Drug Clearance by Multiple Metabolic Pathways: Integration of Hepatic and Intestinal Microsomal and Cytosolic Data [J].
Cubitt, Helen E. ;
Houston, J. Brian ;
Galetin, Aleksandra .
DRUG METABOLISM AND DISPOSITION, 2011, 39 (05) :864-873
[5]   Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach [J].
de Andres, Fernando ;
LLerena, Adrian .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2016, 17 (13) :1159-1180
[6]   Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs) [J].
Duan, Peng ;
Zhao, Ping ;
Zhang, Lei .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (04) :689-705
[7]   Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4 [J].
Fang, J ;
Bourin, M ;
Baker, GB .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1999, 359 (02) :147-151
[8]   Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation [J].
Foti, Robert S. ;
Rock, Dan A. ;
Wienkers, Larry C. ;
Wahlstrom, Jan L. .
DRUG METABOLISM AND DISPOSITION, 2010, 38 (06) :981-987
[9]   Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach [J].
Fuhr, U. ;
Jetter, A. ;
Kirchheiner, J. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) :270-283
[10]   Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies [J].
Goh, BC ;
Lee, SC ;
Wang, LZ ;
Fan, L ;
Guo, JY ;
Lamba, J ;
Schuetz, E ;
Lim, R ;
Lim, HL ;
Ong, AB ;
Lee, HS .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3683-3690